H

Hunan Nucien Pharmaceutical Co Ltd
SSE:688189

Watchlist Manager
Hunan Nucien Pharmaceutical Co Ltd
SSE:688189
Watchlist
Price: 8.67 CNY -1.25% Market Closed
Market Cap: 2.4B CNY

Wall Street
Price Targets

Price Targets Summary
Hunan Nucien Pharmaceutical Co Ltd

There are no price targets for Hunan Nucien Pharmaceutical Co Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Hunan Nucien Pharmaceutical Co Ltd Competitors:
Price Targets
DPHARMA
Duopharma Biotech Bhd
30% Upside
IMP
Imexpharm Corp
1% Downside
200670
Humedix Co Ltd
73% Upside
000661
Changchun High & New Technology Industries Group Inc
32% Upside
PHO
Photocure ASA
4% Upside
MEDCL
Medincell SA
34% Upside
512
Grand Pharmaceutical Group Ltd
55% Upside
VETO
Vetoquinol SA
8% Upside

Revenue
Forecast

Revenue Estimate
Hunan Nucien Pharmaceutical Co Ltd

For the last 6 years the compound annual growth rate for Hunan Nucien Pharmaceutical Co Ltd's revenue is -15%. The projected CAGR for the next 3 years is 38%.

-15%
Past Growth
38%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Hunan Nucien Pharmaceutical Co Ltd

Operating Income forecast
is not available for
Hunan Nucien Pharmaceutical Co Ltd

Net Income
Forecast

Net Income Estimate
Hunan Nucien Pharmaceutical Co Ltd

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Hunan Nucien Pharmaceutical Co Ltd's stock price target?
Not Available

Hunan Nucien Pharmaceutical Co Ltd doesn't have any price targets made by Wall Street professionals.

What is Hunan Nucien Pharmaceutical Co Ltd's Revenue forecast?
Projected CAGR
38%

For the last 6 years the compound annual growth rate for Hunan Nucien Pharmaceutical Co Ltd's revenue is -15%. The projected CAGR for the next 3 years is 38%.

Back to Top